News Image

Why NASDAQ:AMPH is Poised for High Growth.

By Mill Chart

Last update: Jan 16, 2024

In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our CANSLIM growth screen, which makes it worth to investigate a bit more.

Looking into the canslim metrics of AMPHASTAR PHARMACEUTICALS IN

  • The recent financial report of AMPHASTAR PHARMACEUTICALS IN demonstrates a 203.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
  • With impressive quarter-to-quarter (Q2Q) revenue growth of 50.37%, AMPHASTAR PHARMACEUTICALS IN showcases its ability to generate increased sales and revenue. This growth indicates the company's strong customer demand and its effective business strategies.
  • AMPHASTAR PHARMACEUTICALS IN has achieved 77.88% growth in EPS over the past 3 years, reflecting a sustained improvement in earnings performance.
  • With a favorable Return on Equity (ROE) of 22.72%, AMPHASTAR PHARMACEUTICALS IN demonstrates its ability to deliver attractive returns for shareholders. This metric highlights the company's effective management of assets and its profitability.
  • AMPHASTAR PHARMACEUTICALS IN has maintained a healthy Relative Strength (RS) over the analyzed period, with a current 94.89 rating. This demonstrates the stock's ability to outperform its peers and indicates its competitive positioning. AMPHASTAR PHARMACEUTICALS IN is well-positioned for potential price growth opportunities.
  • AMPHASTAR PHARMACEUTICALS IN exhibits a favorable Debt-to-Equity ratio at 1.07. This highlights the company's ability to limit excessive debt levels and maintain a strong equity base, demonstrating its financial stability and risk management practices.
  • AMPHASTAR PHARMACEUTICALS IN exhibits a favorable ownership structure, with an institutional shareholder ownership of 66.52%. This signifies a diverse investor base, which can contribute to a more stable and efficient market for the stock.

Analyzing the Technical Aspects

Every day, ChartMill assigns a Technical Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various technical indicators and properties.

We assign a technical rating of 7 out of 10 to AMPH. This is due to a consistent overall performance, although we see some doubts in the very recent evolution. In the medium time frame things are still looking good.

  • Looking at the yearly performance, AMPH did better than 94% of all other stocks. We also observe that the gains produced by AMPH over the past year are nicely spread over this period.
  • AMPH is part of the Pharmaceuticals industry. There are 204 other stocks in this industry. AMPH outperforms 90% of them.
  • The short term trend is negative, but the long term trend is still positive. So although the long term is still positive, this may be a trend turning.
  • AMPH is currently trading in the middle of its 52 week range. The S&P500 Index however is currently trading near new highs, so AMPH is lagging the market.

Our latest full technical report of AMPH contains the most current technical analsysis.

A complete fundamental analysis of NASDAQ:AMPH

ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to AMPH. AMPH was compared to 204 industry peers in the Pharmaceuticals industry. While AMPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMPH is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make AMPH a good candidate for value and growth investing.

Check the latest full fundamental report of AMPH for a complete fundamental analysis.

More growth stocks can be found in our CANSLIM screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.



NASDAQ:AMPH (5/24/2024, 7:13:49 PM)

After market: 43 -0.26 (-0.6%)


-0.09 (-0.21%)


News Image11 days ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Image12 days ago - ChartmillExploring NASDAQ:AMPH's growth characteristics.

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations

News Image18 days ago - InvestorPlaceAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image18 days ago - BusinessInsiderAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...

News Imagea month ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)
News Imagea month ago - Market News VideoCommit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals Becomes Oversold (AMPH)
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
News Image3 months ago - Seeking AlphaAmphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image3 months ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image4 months ago - Market News VideoAMPH Crosses Below Key Moving Average Level
News Image4 months ago - InvestorPlace3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

AMPH Links
Follow us for more